All In Biotech

Drug Trial Radar · NCT02752074

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 706 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

706

Actual

Start

Jun 21, 2016

Primary completion

Jan 8, 2018

Study completion Aug 16, 2019

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma

Conditions

  • Melanoma

Interventions

  • pembrolizumab + epacadostatDrug

    * Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Epacadostat will be administered orally daily starting at Day 1 (Week 1)

  • pembrolizumab + placeboDrug

    * Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1) * Placebo will be administered orally daily starting at Day 1 (Week 1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free SurvivalTime frame: Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
  2. Overall Survival (OS) Rate at 6 MonthsTime frame: Assessed every 9 weeks of study participation which is estimated to be 24 months. The OS rate at Month 6 was calculated.

Locations

129 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Santa Monica, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Iowa City, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lutherville, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Fridley, Minnesota

  • Site not named

    Billings, Montana

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Fairfax, Virginia

  • Site not named

    Spokane, Washington

  • Site not named

    Camperdown, New South Wales, Australia

  • Site not named

    Westmead, New South Wales, Australia

  • Site not named

    Wollstonecraft, New South Wales, Australia

  • Site not named

    Cairns, Queensland, Australia

  • Site not named

    Greenslopes, Queensland, Australia

  • Site not named

    Kurralta Park, South Australia, Australia

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.